A detailed history of Driehaus Capital Management LLC transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Driehaus Capital Management LLC holds 1,721,296 shares of PCVX stock, worth $149 Million. This represents 1.93% of its overall portfolio holdings.

Number of Shares
1,721,296
Previous 1,934,747 11.03%
Holding current value
$149 Million
Previous $146 Million 34.52%
% of portfolio
1.93%
Previous 1.58%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$70.52 - $117.12 $15.1 Million - $25 Million
-213,451 Reduced 11.03%
1,721,296 $197 Million
Q2 2024

Aug 14, 2024

BUY
$60.06 - $78.77 $4.02 Million - $5.27 Million
66,940 Added 3.58%
1,934,747 $146 Million
Q1 2024

May 15, 2024

BUY
$59.79 - $81.05 $11.6 Million - $15.7 Million
193,439 Added 11.55%
1,867,807 $128 Million
Q4 2023

Feb 14, 2024

BUY
$45.35 - $63.41 $15.9 Million - $22.2 Million
350,484 Added 26.47%
1,674,368 $105 Million
Q3 2023

Nov 14, 2023

BUY
$46.0 - $53.1 $6.17 Million - $7.12 Million
134,027 Added 11.26%
1,323,884 $67.5 Million
Q2 2023

Aug 14, 2023

BUY
$34.66 - $54.07 $20 Million - $31.1 Million
575,951 Added 93.82%
1,189,857 $59.4 Million
Q1 2023

May 15, 2023

SELL
$36.27 - $47.2 $7.87 Million - $10.2 Million
-216,889 Reduced 26.11%
613,906 $23 Million
Q4 2022

Feb 14, 2023

BUY
$20.58 - $47.95 $5.09 Million - $11.9 Million
247,189 Added 42.36%
830,795 $39.8 Million
Q3 2022

Nov 14, 2022

BUY
$21.69 - $28.53 $768,173 - $1.01 Million
35,416 Added 6.46%
583,606 $14 Million
Q2 2022

Aug 15, 2022

BUY
$17.68 - $26.58 $8.1 Million - $12.2 Million
458,190 Added 509.1%
548,190 $11.9 Million
Q1 2022

May 16, 2022

BUY
$17.46 - $26.36 $1.57 Million - $2.37 Million
90,000 New
90,000 $2.17 Million

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $5.13B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Driehaus Capital Management LLC Portfolio

Follow Driehaus Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Driehaus Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Driehaus Capital Management LLC with notifications on news.